Skip to main content
Signal8

BioLineRx Ltd. (BLRX) Form 6-K — May 22, 2026

$BLRXForm 6-KFiled May 22, 2026, 7:00 AM ET0001178913-26-002876Original filing

BioLineRx and partner Hemispherian AS are presenting two abstracts on GLIX1 at the ASCO 2026 Annual Meeting, highlighting preclinical data for this first-in-class oral TET2 activator in glioblastoma and other cancers. The data demonstrates that GLIX1 effectively restores TET2 activity, leading to tumor-selective DNA damage, with strong antitumor activity in glioblastoma xenograft models and efficient brain penetration (68-85% of plasma levels). A second abstract outlines synergistic antitumor activity when combining GLIX1 with PARP inhibitors across multiple cancer types, providing a mechanistic rationale for future combination trials.

Key figures

Abstract numbers
["e14072","e13129"]
Max dose dogs mg kg
1000
Max dose rats mg kg
2000
Trial patients part1
30
Brain exposure percent
68-85% of plasma levels

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.